• Lung Cancer Edition: Top Headlines for Week of September 16, 2024

  • Sep 19 2024
  • Length: 14 mins
  • Podcast

Lung Cancer Edition: Top Headlines for Week of September 16, 2024

Listen for free

View show details

  • Summary

  • In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.

    Read the full coverage here:

    FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy

    Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’

    Perioperative nivolumab improves outcomes in resectable NSCLC

    Despite progress, barriers to lung cancer biomarker testing persist

    Atezolizumab regimen ‘merits further study’ for unresectable NSCLC

    References:

    Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

    Press Release

    Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.

    Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

    Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
    Show more Show less
Show more Show less

What listeners say about Lung Cancer Edition: Top Headlines for Week of September 16, 2024

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available